HC Wainwright Issues Pessimistic Outlook for RMTI Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities researchers at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Rockwell Medical in a research report issued to clients and investors on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.01) for the quarter, down from their previous forecast of $0.02. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q3 2025 earnings at ($0.01) EPS and Q4 2025 earnings at $0.01 EPS.

Several other analysts have also recently commented on RMTI. RODMAN&RENSHAW raised Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw started coverage on Rockwell Medical in a research report on Thursday, November 14th. They issued a “buy” rating and a $5.00 target price for the company. Finally, StockNews.com cut Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st.

Rockwell Medical Stock Performance

Shares of Rockwell Medical stock opened at $2.22 on Tuesday. The stock has a market cap of $71.75 million, a PE ratio of -44.40 and a beta of 1.50. The business has a fifty day simple moving average of $3.43 and a 200-day simple moving average of $2.66. The company has a quick ratio of 2.00, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. Rockwell Medical has a 12 month low of $1.16 and a 12 month high of $5.15.

Institutional Trading of Rockwell Medical

A number of institutional investors have recently bought and sold shares of the company. XTX Topco Ltd boosted its position in Rockwell Medical by 45.7% during the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock valued at $113,000 after purchasing an additional 8,922 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new stake in Rockwell Medical during the third quarter valued at $40,000. Verus Capital Partners LLC acquired a new stake in shares of Rockwell Medical in the third quarter worth about $51,000. State Street Corp boosted its stake in shares of Rockwell Medical by 21.5% during the 3rd quarter. State Street Corp now owns 95,004 shares of the company’s stock worth $377,000 after acquiring an additional 16,800 shares in the last quarter. Finally, Barclays PLC bought a new stake in shares of Rockwell Medical during the 3rd quarter worth about $90,000. Institutional investors and hedge funds own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.